汤剂
药方
医学
传统医学
冠心病
心脏病学
内科学
药理学
作者
Xuezhen Wang,Xunyan Xing,Peifeng Huang,Zhibin Zhang,Zehua Zhou,Leiqin Liang,Rongmei Yao,Xuerun Wu,Long Yang
出处
期刊:Heliyon
[Elsevier BV]
日期:2024-04-01
卷期号:10 (7): e28919-e28919
被引量:13
标识
DOI:10.1016/j.heliyon.2024.e28919
摘要
Through this study, we found that XFZYD has a significant therapeutic effect in the clinical treatment of coronary heart disease, which can play a role in the treatment of CHD by inhibiting atherosclerosis, inhibiting cardiovascular remodeling, improving oxidative stress damage, improving hemorheology, improving myocardial fibrosis and other mechanisms. Through computer simulation, it was found that the main effective components of XFZYD treatment for CHD were quercetin, kaempferol and luteolin, and the key core targets were IL6, VEGFA and P53, and each component had a high VEGFA libdock score. It is speculated that VEGFA is the key target of XFZYD in the treatment of CHD. Kaempferol and VEGFA had the highest libdock score. kaempferol and IL6 have the highest number of hydrogen bonds, kaempferol and IL6 have the highest number of hydrogen bonds, which indicates that they are most stable, indicating that kaempferol is the key component of XFZYD in the treatment of CHD, which provides a theoretical basis for follow-up experimental research.
科研通智能强力驱动
Strongly Powered by AbleSci AI